Arch Therapeutics, Inc. (OTCMKTS:ARTH) Sees Significant Decrease in Short Interest

Arch Therapeutics, Inc. (OTCMKTS:ARTH) was the recipient of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 13,200 shares, a decline of 9.6% from the October 31st total of 14,600 shares. Based on an average trading volume of 13,900 shares, the days-to-cover ratio is currently 0.9 days.

Arch Therapeutics Price Performance

Arch Therapeutics stock traded down $0.01 during trading on Tuesday, hitting $0.20. The stock had a trading volume of 65,962 shares, compared to its average volume of 5,506. The stock’s 50 day moving average is $0.31 and its two-hundred day moving average is $0.66. Arch Therapeutics has a 1 year low of $0.17 and a 1 year high of $18.00.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc, together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease.